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Abstract: Both external radiation exposure and internal radionuclide contamination are 
well known risk factors in the development of thyroid epithelial tumors. The identification 
of specific molecular markers deregulated in radiation-induced thyroid tumors is important 
for the etiological diagnosis since neither histological features nor genetic alterations can 
discriminate between sporadic and radiation-induced tumors. Identification of highly 
discriminating markers in radiation-induced tumors is challenging as it relies on the ability to 
identify marker deregulation which is associated with a cellular stress that occurred many 
years before in the thyroid cells. The existence of such a signature is still controversial, as it 
was not found in several studies while a highly discriminating signature was found in both 
post-radiotherapy and post-Chernobyl series in other studies. Overall, published studies 
searching for radiation-induced thyroid tumor specificities, using transcriptomic, proteomic 
and comparative genomic hybridization approaches, and bearing in mind the analytical 
constraints required to analyze such small series of tumors, suggest that such a molecular 
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signature could be found. In comparison with sporadic tumors, we highlight molecular 
similarities and specificities in tumors occurring after high-dose external radiation exposure, 
such as radiotherapy, and in post-Chernobyl tumors that occurred after internal 
131I 
contamination. We discuss the relevance of signature extrapolation from series of tumors 
developing after high and low doses in the identification of tumors induced at very low 
doses of radiation. 
Keywords:  thyroid; radiation-induced tumors; transcriptomic signature; molecular 
epidemiology 
 
1. Radiosensitivity of Thyroid Tissue in Childhood 
Radiation exposure during childhood is a well demonstrated pro-tumorigenic factor for thyroid 
tissues. Increased risk of developing a thyroid tumor has been reported in epidemiologic studies on 
cohorts of children or young adults externally exposed during radiotherapy for benign diseases or for a 
primary cancer [1–3] and after the atomic bombing of Japan [4] or internally contaminated by 
131I after 
Chernobyl fallout [5,6]. Thyroid tissue radiosensitivity in adults is much lower than for children, if  
it exists [7,8]. The reported excess relative risk of thyroid cancer exposure is at its highest when 
exposure occurs in early childhood and decreases with exposure at older age; some other factors, such as 
gender or iodine supply, may modify the risk [7,8]. It was an estimated 1.31 per Gray (Gy) in a study 
analyzing a cohort of childhood cancer survivors [2], 1.91 per Gray (Gy) in a recent study analyzing a 
post-Chernobyl Ukrainian cohort [9], 7.7 per Gy in a meta-analysis of several studies of externally 
exposed cohorts [10], and even higher in Hiroshima-Nagasaki cohorts. The risk is significant for doses  
as low as 0.1 Gy [10], increases linearly with doses up to 15–20 Gy [2], and then decreases because of a  
cell-killing effect at higher doses. Analysis of the Israël tinea capitis cohort, covering a dose range 
below 0.1 Gy, by Ron et al. and Sadetzki et al.; reported an ERR per Gy of 32.5 and 20.2, respectively 
[10,11]. However, estimation of the risk measured with this series is much higher than any other series 
and may not be extrapolated to others series since unique genetic background is suspected [11]. The 
risk peaks 15 years after exposure but remains significant over decades, more than 40 years in the 
study by Ron et al. [10]. Accordingly, an excess of thyroid cancer is still being observed   
post-Chernobyl, mainly in people exposed at younger ages [9]. 
2. Do Radiation-Induced Thyroid Tumors Show Specific Clinical Features? 
Radiation-induced thyroid cancers are mainly papillary thyroid carcinomas (PTCs) which are also 
predominantly found in sporadic tumors. PTCs are found almost exclusively among short latency post-
Chernobyl tumors, and include a high percentage of solid PTC variants, but this is related more to the 
association of the solid PTC variant with younger age of diagnosis of the tumor rather than with the 
radiation exposure [12,13]. The effect of low-iodine diet has also been reported as a risk factor for the 
development of these thyroid tumors, both by increasing the uptake of radioiodine in the thyroid and 
therefore the dose of radiation delivered to the thyroid gland and by promoting thyroid cancer growth Genes 2012, 3                                      
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[14,15]. Follicular adenomas and a few follicular carcinomas are also found in cohorts exposed to 
radiation [12,15–18]. 
An increased frequency of RET/PTC rearrangement over BRAF mutations is associated with 
radiation-induced DNA breakdown, but such an increase is also found in the absence of radiation 
exposure in young patients as compared with adult tumors. A disequilibrium of RET/PTC3 over 
RET/PTC1 has been described, and is associated with the short latency solid variant of PTC. Increased 
aggressiveness of radiation-induced tumors is also a feature associated with short latency pediatric 
tumors, including solid PTC variants [14,15,19,20], indicating that age at diagnosis more than 
radiation exposure is the parameter correlated with aggressiveness [19]. The nature and the frequency 
of molecular alterations found in radiation-induced tumors are associated with many parameters (age at 
radiation exposure, radiation dose, latency for tumor occurrence or histological subtype or other factors) 
unrelated to radiation exposure [21–27]. Thus, no etiology imprinting is currently suspected in a given 
tumor regarding clinical data, histopathological features and molecular alterations. 
3. High-Throughput Molecular Studies of Radiation-Induced Thyroid Tumors: Can They 
Identify Discriminating Radiation-Induced Markers? 
Radiation-induced molecular specificities have been sought using transcriptome analysis [28–34], 
proteome analysis [35,36] and genomic analysis [32,37–39]. Few studies have been published to date 
and most have focused on post-Chernobyl tumors due to internal 
131I contamination; only one study 
has reported the identification of a discriminating transcriptomic radiation-induced signature after 
external exposure (post-radiotherapy) [33]. 
In two of these studies, molecular specificities of post-Chernobyl tumors were sought but not found 
at the transcriptomic level [28,31], and the authors suggested that radiation-induced and sporadic 
thyroid tumors have very similar transcriptomic patterns. However, the other studies have found sets of 
deregulated genes/proteins that more or less accurately identified post-Chernobyl [29,30,34,35], or 
post-radiotherapy induced tumors [33] from sporadic tumors (Table 1). However, only one group went 
one step further, by testing the robustness of the signatures by blind identification of the etiology of an 
independent series of thyroid tumors [33,34]. 
To date, limited overlap exists between the genes found to be deregulated in these studies 
(Supplementary table) and this may be due to differences in microarray platforms, data analysis and 
normalization, false positive rate, methods of tumor clustering, small size of the series [40], and/or 
specificities of the series of tumors (Table 1). For example, in comparison with other series of tumors, 
Abend et al. studied the transcriptome and the proteome of post-Chernobyl PTCs of shorter latency 
and compared them with those of sporadic tumors diagnosed in older patients as compared with other 
series. As expected, their markers suggested a higher aggressiveness of radiation-induced compared to 
sporadic tumors [30,35]. Other possible explanations of this low overlap between deregulated genes in 
the literature stem from the fact that published studies have not explored or reported full microarray 
data. Published sets of genes are sometimes limited to subsets of the identified deregulated genes [30] 
or to genes deregulated in post-Chernobyl versus normal tissue by subtraction of the genes already 
deregulated in sporadic PTCs versus normal tissue, thus eliminating genes that could be deregulated in 
both cases but at different levels [32]. Moreover, some authors focused on molecular mechanisms Genes 2012, 3                                      
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related to DNA repair, radiation, H2O2 or stress cellular response, and removed from analysis all   
genes of the immune response [29,41], these are however one of the radiation-associated features in 
other studies [30,33]. 
Molecular specificities of radiation-induced tumors are also sustained by a recent genomic approach 
used to analyze age at diagnosis- and ethnicity-matched sporadic and post-Chernobyl pediatric PTCs 
and identified a radiation-induced specific gain on chromosome 7q11.22–11.23 [38]. This locus 
includes genes involved in DNA repair, response to DNA damage and cell adhesion, and these 
categories of genes were previously reported to be abnormally expressed in several transcriptomic 
studies [29,30,33,34]. 
All this data suggests that molecular markers for classifying radiation-induced and sporadic thyroid 
tumors do exist, but most authors have not fully explored their data. Moreover, not all the usual 
bioinformatic tools for transcriptomic analysis are fully appropriate for the analysis of small series of 
radiation-induced tumors [31,34]. 
4. Highly Discriminating Radiation-Induced Thyroid Tumor Signature: Is It a Question  
of Methodology? 
Whatever the tumor type a transcriptomic signature for classifying tumors could be masked or 
spoiled by the background noise inherent in the microarray technique, because most levels of gene 
expression do not differ significantly from one group to another and because of the possible 
heterogeneity of gene expression within a given subgroup of tumors [42]. Moreover, confounding 
factors such as age at irradiation and diagnosis, histology, gender, and gene alterations could, as a 
function of the methodology, result in biased selection of genes. Finally, the validation of the 
signature, by testing if it is suitable to blindly discriminate tumors, necessitates keeping apart a group 
of tumors. Of course, all these limitations are even more crucial when working with rare tumors (small 
series) such as radiation-induced tumors (Table 1). It is therefore hard to find the balance between a 
number of tumors that is large enough to find the signature, while having also enough tumors for the 
statistical validation of the signature prediction. Consequently, well-known conventional microarray 
analysis methods, which were successfully used in large tumor series and/or in series displaying a 
limited intra-group heterogeneity, appeared unsuitable for small series of radiation-induced thyroid 
tumors. Specifically, unsupervised or supervised tumor classification, generalized partial least-square, 
random forest, linear kernel support vector machine, prediction analysis of microarray, significance 
analysis of microarrays, gene expression bar code, top-scoring pair(s) and a PCA-based method 
applied by us and others, have either identified signatures of poor robustness [29,34], or have failed to 
find any signature [28,31] in post-radiotherapy or post-Chernobyl series. 
 Genes 2012, 3                                    
 
23
Table 1. Published studies analyzing molecular transcriptomic or proteomic specificities of radiation-induced thyroid cancers. 
 Study  Port  et al.; 2007  Detours et al.; 2007  Stein et al.; 2010 
1 Ugolin  et al.; 
2,3 Ory  et al.; 2011 
3 Boltze  et al.; 2009 
 Exposure  Post-Chernobyl Post-Chernobyl  Post-Chernobyl  Post-Chernobyl Post-radiotherapy  Post-Chernobyl 
R
a
d
i
a
t
i
o
n
-
i
n
d
u
c
e
d
 
Tumor set  11 PTC 
6 
3 males, 8 females 
12 PTC 
4 males, 8 females 
10 PTC 
Half male and half female 
Learning set: 6 PTC 
3 males, 3 females 
Learning set: 7 rPTC, 
7rFTA 
4 males, 10 females 
86 PTC 
40 males, 46 females 
Age at IR  /  1–16 years(M = 8.6 years)  2 month–14 years (M = 6 years)  10–16 years  
(M = 12.7 years) 
3–14 years (M = 8.6 years)  3–23 years  
(M = 11.8 years) 
Age at 
diagnosis 
15–22 years  
(M = 18 years) 
16–33 years  
(M = 24 years) 
14–28 years (M = 20 years)  27–33 years  
(M = 29.2 years) 
20–56 years  
(M = 35.1 years) 
12–28 years  
(M = 18.6 years) 
Latency  Up to 15 years after 1986  15–17 years  
(M = 16 years) 
14–16 years (M = 13.6 years)  16–17 years  
(M = 16.5 years) 
11–48 years  
(M = 26.5 years) 
Up to 15 years after 
1986 
(mean = 6.8 years) 
Dosimetry  90% at 0.15-1Gy 
4  /  /  /  12–42.5 Gy (M = 14.1 Gy)  90% at 0.15-1Gy 
4 
Histology 
Mutations 
Others 
PTC 
2 PTC1; PTC3 
6 
T2N0M0 to T4N1M1 
8 PTC, 3 FVPTC, 1 PTC 
5 BRAF; 5 PTC 
/ 
PTC 
1 PTC; 1 PTC3 
/ 
? 
7 
4 BRAF; 1 RET/PTC 
/ 
7 FTA; 6 PTC; 1 FVPTC 
1 BRAF; 1 RAS 
5 with chemotherapy 
PTC 
S
p
o
r
a
d
i
c
 
Tumor set  41 PTC 
19 males, 22 females 
14 PTC 
7 
5 males, 9 females 
20 PTC from He et al. study 
5 
8 males, 12 females
 
Learning set: 7 PTC 
4 males, 3 females 
Learning set: 7 sPTC, 
7sFTA 
5 males, 9 females 
91 PTC 
49 males, 42 females 
Age at 
diagnosis 
15–83years (M = 60 years)  29–68 years (M = 47 
years) 
13–65 years (M = 44.4 years)  29–38 years  
(M = 34.6 years) 
21–63 years  
(M = 37.6 years) 
15–83 years  
(M = 50.1 years) 
Histology 
Mutations 
Others 
PTC 
6 
5 PTC1 
T1N0-1M0 (n = 26)  to 
T3N1M0 
9 PTC, 4 FVPTC, 1 tPTC 
5/14 BRAF; 3/14 
RET/PTC 
/ 
14 PTC; 5 FVPTC; 1 HCC
7 
/ 
/ 
/ 
7 
2 BRAF; 1 RET/PTC 
 
7 FTA; 5 PTC; 2 FVPTC 
4 BRAF; 2 RAS, 1 PTC1,  
1 PTC3 
None with chemotherapy 
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Table 1. Cont. 
 Study  Port  et al.; 2007  Detours et al.; 2007  Stein et al.; 2010 
1 Ugolin  et al.; 
2,3 Ory  et al.; 2011 
3 Boltze  et al.; 2009 
 Arrays  Human genome survey 
microarray V2.0 (Applied 
Biosystems)  
(33,000 probes) 
Human 1 cDNA 
Microarray slides (Agilent 
Technologies).  
(19,000 probes) 
Hybridized with normal 
matched tissue 
Affymetrix U133A Array  
(20,000 probes) (Stein et al.) 
Affymetrix U133 Plus 2.0 Array 
 (50,000 probes) (He et al.) Hybridized 
with normal matched tissue 
Dataset  retrieved from GEO 
(GSE3950) 
Human 25K 50–52mer  
oligo-microarrays (national 
genomic platform) 
Hybridized with an internal 
reference (pool of normal 
thyroid tissues) 
(Not relevant) 
 Analysis  Identified 1300 genes  
up- or downregulated at least 
fivefold  (pool of 10 rPTC vs. 
pool of 10 sPTC) 
Validation of 92 more 
deregulated genes in the full 
tumor series by  
RT-PCR 
(1) Several  methods 
applied for tumor 
classification 
(2) Same  methods  applied 
for tumor 
classification by using 
a -irradiation vs. 
H2O2 lymphocyte 
response signature. 
Compared two sets of deregulated 
genes obtained separately:  
(1) post-Chernobyl PTC vs. normal 
tissues and; (2) sporadic PTC vs. 
normal tissues 
Retained the genes deregulated in post-
Chernobyl PTC only 
106 genes discriminating 
signature identified by 
applying the EMts_PCA on 
the learning/training set  
651 deregulated genes 
identified 
322-gene discriminating 
signature identified by 
applying the EMts_PCA to 
the learning/training set  
1900 deregulated genes 
identified 
Identification of protein 
markers by MALDI-
TOF mass 
spectrophotometry 
20 candidate protein 
markers analyzed by 
immunochemistry 
 Results  10 genes for complete 
separation of the groups (no 
validation on an independent 
tumor sets) 
In both cases classification 
with error rate errors of 8 
to 42% for sporadic 
tumors and  
7 to 29% for post-
Chernobyl tumors 
Identified 177 deregulated genes 
unique to the radiation-induced tumors 
Etiology prediction of the  
13 remaining tumors using 
the 106 gene signature  
(1 unclassified, non 
misclassified)  
Blind prediction of 
 etiology of the  
29 remaining tumors 
(tumors (13 rPTC or FTA; 
16 sPTC FTA)  
(1 unclassified,  
2 misclassified) 
Combination of 6 of 
these markers separates 
the groups (no 
validation on an 
independent tumor sets) 
PTC: Papillary thyroid carcinoma; FVPTC: PTC, follicular variant, tPTC: PTC, trabecular variant; PTCs: PTC, solid variant; HCC: Hurthle cell carcinoma (HCC with follicular and papillary features); FTA: 
follicular thyroid adenoma; rPTC, rFTA: radiation-induced PTC; FTA; sPTC, sFTA: sporadic PTC; FTA; RAS: mutation in NRAS, HRAS or KRAS gene; BRAF: V600E BRAF mutation; PTC (unspecified), PTC1, 
PTC3: RET/PTC rearrangement; M: mean; 
1 Transcriptome analysis was performed on 10 out 14 PTC tumors described in Stein et al. [32]. Clinical data are given for the full tumor set; 
2 From Detours et al. [29]. For the 
analysis described in Ugolin et al. [34], 6 out of 12 post-Chernobyl PTCs and 7 out 14 sporadic PTCs of the tumor set described by Detours et al. [29], were used as a learning/training set for signature identification, the 
remaining tumors were used as testing set. Clinical data are given for the learning/training set; 
3 Clinical data are given for the learning/training set; 
4 Estimation from general dosimetry data; 
5 From the He et al. 
study, 2005 (GSE3467); 
6 No indication of the 10 tumors used for pool; 
7 No indication of the precise histology by tumor. Genes 2012, 3                                    
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To circumvent these limitations, we have proposed a new microarray analysis strategy, the 
EMts_2PCA method ([34], see supplementary data), which is specifically adapted to identify sets of 
genes with a high discriminating potential by using small series of samples (as small as 6–7 tumors in 
each sporadic and radiation-induced group) and which greatly limits the effect of confounding factors 
(sex, age at diagnosis, gene alteration, histology, TNM classification..) in the signature of interest, as 
the search for discriminating genes can be focused specifically on one criterion, for example the 
etiology. Robustness of the signature is then assessed by the blind validation on an independent set of 
tumors at least of the same size as the tumor set used to identify the signature [34]. This strategy was 
successfully used to find discriminating signatures in series of post-radiotherapy and post-Chernobyl 
thyroid tumors [33,34], but also in radiation-induced sarcomas [43], and in radiation-induced breast 
tumors by reanalyzing the published dataset of Broeks et al. [34,44]. 
Thus, by using a dedicated method, such as EMts_2PCA, focused on the identification of markers 
of high potential for etiology prediction and which greatly limits the effect of confounding factors,  
a radiation-induced highly discriminating signature was identified in both post-Chernobyl and   
post-radiotherapy thyroid tumors. 
5. Are Specific Molecular Pathways Deregulated in Radiation-Induced Thyroid Tumors? 
Despite the limited overlap in term of genes markers, analysis of the deregulated genes identified in 
radiation-induced tumors, in terms of functional categories or molecular pathways, give some 
preliminary indications about thyroid radiation-induced tumorigenesis. Upregulated genes identified 
by Port et al. are mainly associated with signal transduction (G proteins, VEGF-A, PDGF-B and   
EGF signaling pathways) and metabolic processes (oxidoreductases related to fatty acid desaturation, 
and steroid metabolism). Downregulated genes are mainly associated with the immune response, 
signal transduction (G protein and cytokines/chemokines) and cell communication/adhesion [30]. 
Immune response and signal transduction pathways including EGFR, MAPK, Rac/cdc42, hedgehog, 
TGF/BMP, calcium signaling and WNT canonical and noncanonical pathways are also deregulated  
in post-radiotherapy tumors [33]. Detours, et al. suggested that genes deregulated in post-Chernobyl 
tumors are mainly involved in cellular responses to -radiation and DNA double-strand break   
repair while sporadic tumors deregulated genes seem to bear the hallmark of the oxidative stress 
response [29]. However, analysis of the same series of tumors showed that post-Chernobyl tumors 
displayed a pattern of both DNA repair (including double-strand breaks, base and mismatch repair) and 
oxidative stress response [34]. The set of markers identified by Stein et al. [32] included predominant 
functional categories such as connective tissue development, cancer, cell cycle, gene expression, with a 
significant tendency to nucleic acid metabolism, the latter being also highly deregulated in the study by 
Ugolin et al. [34]. In the study of Stein et al., most of the post-Chernobyl deregulated genes were 
associated with an ESR1 and/or TERT focused network [32], while both ESR1 and ESR2 were found 
to be downregulated in post-radiotherapy tumors [33]. 
Interestingly, genes identified as participants in the response of the non-tumorigenic human thyroid 
epithelial cell line Htori-3 to high-linear energy transfer particles [45], in the human thyroid papillary 
carcinoma cell line TPC-1 to various doses of X-rays [46], or as participants in the specific response of 
human thyroid tissue transplanted in SCID mice to 
137Cs or neutrons [47], are also found deregulated Genes 2012, 3                                    
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in radiation-induced thyroid tumors both in post-Chernobyl and post-radiotherapy series and may be 
markers of radiation exposure whatever the dose, dose rate, external radiation or internal 
contamination (Supplementary table). 
6. Imprinting of Radiation-Induced Thyroid Tumors: Impact of the Mode of Exposure, Dose and 
Dose Rate 
Both external exposure and contamination can induce thyroid tumors, but the relevance of 
extrapolation of conclusions from data on tumors occurring after exposure to external radiation, such 
as radiotherapy, to post-Chernobyl tumors that occurred after internal 
131I contamination still has not 
been investigated. Chernobyl-exposed people received a median radiation dose of 0.37 Gy to the 
thyroid, and the dose ranged from less than 0.1 Gy to 10 Gy [48,49] while, in the case of thyroid 
tumors that develop after radiotherapy for a primary cancer during childhood, such as Hodgkin disease, 
the dose to the thyroid could easily be above the 15–20 Gy limit for observation of the cell-killing 
effect in thyroid tissue [2,33]. Thus, the impact of the dose to the thyroid may also be determinant  
for the selection of specific molecular mechanisms in the tumor in relation to the amount of DNA 
damage and the severity and nature of the cellular stress which the damaged thyrocytes will have to 
survive to lead to a tumor. In the context of the identification of a radiation-induced signature, the 
extent of similarity and specificities of molecular mechanisms in external exposure-induced and 
contamination-induced tumorigenesis and the impact of the dose are crucial as this should determine 
the possibility of identifying a general radiation-induced signature or should limit the use of mode of 
exposure- and dose range specific signatures for high robustness prediction. 
Comparative analysis of the pathways deregulated in a post-radiotherapy and in a post-Chernobyl 
series [33,34], with the restriction that the series were not analyzed by using the same arrays, showed, 
however, that both post-Chernobyl and post-radiotherapy PTCs are deregulated in common molecular 
pathways associated with cellular response to radiation and oxidative stress, or signal transduction 
[50]. Particularly, the WNT canonical and noncanonical pathways, and other potentially   
co-deregulated pathways (Sonic hedgehog, Notch, and EGF pathways), which were first identified  
in post-radiotherapy tumors [33], were also deregulated in post-Chernobyl tumors (Figure 1). This 
strongly suggests that post-Chernobyl and post-radiotherapy tumors display a common core of 
molecular markers, while a fully comparable analysis of post-radiotherapy and post-Chernobyl tumors 
is needed to decide on the similarities and specificities of thyroid tumors following external exposure or 
contamination. Moreover, the 5-gene overlap between the 106-gene post-Chernobyl and the 322-gene 
post-radiotherapy discriminating signatures can classify both series of tumors [50]. Overall, this data 
suggests that the molecular imprinting found in radiation-induced tumors likely includes the molecular 
consequences of the initial stress associated with radiation exposure in thyroid tissues and that part of 
this imprinting is independent of dose, dose rate and route of exposure, at least for doses above 0.1 Gy. 
These data are in agreement with the similar risk factors found for thyroid tumors either at 
Chernobyl or following external radiation exposure. It should also be noted that a common signature 
was found for both thyroid adenomas and PTC [33], which is also in accordance with epidemiological 
data that showed similar risk factors for both. Genes 2012, 3                                    
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Whether this imprinting denotes exposure to previous radiation or is a hallmark of   
radiation-tumorigenesis remains to be shown, by comparing gene expression in non tumoral thyroid 
tissue previously exposed or not to radiation.  
Figure 1. Signal transduction pathways associated with the WNT canonical and 
noncanonical pathways deregulated in radiation-induced thyroid tumors. The figure gives a 
simplified overview of the WNT canonical pathway with potential connections with the 
EGFR, SHH, NOTCH and BMP pathways (A) and the WNT noncanonical pathway (B). 
Genes deregulated in post-radiotherapy tumors are indicated by a yellow square, and   
green or orange circles indicate the genes deregulated in post-Chernobyl tumors, from 
Ugolin  et al. [34], or from other studies, respectively. Genes selected in either the   
post-radiotherapy or the post-Chernobyl signatures (high discriminating potential, see 
supplementary data) [33,34], are indicated in grey boxes. Blue circles indicate the genes 
deregulated in studies analyzing the cellular response of thyroid models to radiation 
exposure. The dotted line indicates the genes reported to be deregulated (mRNA or protein) 
in studies of sporadic thyroid tumorigenesis. 
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Figure 1. Cont. 
 
7. The Persistent Problem of Low Doses: Can We Evaluate the Risk of Thyroid Cancers for 
Doses Lower Than 0.1 Gy? 
As reported in the studies mentioned above and many others, an increase in thyroid tumor incidence 
is expected and could be measured by conventional epidemiology for doses above 0.1 Gy, but for 
lower doses, the risk is not proven. For radiation protection purposes, a linear non-threshold model is 
applied to extrapolate the risk observed at high doses to low doses [51–53]. But strictly, evaluation of 
such a risk is outside the limits of conventional epidemiology and we do not know to date if a thyroid 
exposure to such low doses could effectively lead to the development of thyroid tumors. 
In any case at low doses, if this risk does exist, a very low number of radiation-induced thyroid 
tumors is expected and will be masked among the high number of sporadic tumors which has regularly 
increased all over the world for more than 25 years due to better detection and diagnosis of thyroid 
diseases [54–57]. To be used for the detection of these radiation-induced tumors, any test should have 
predictive values close to 100%. 
Because of a lack of identified low-dose radiation induced thyroid tumors, we do not know if the 
molecular signatures found in tumors that developed after exposure to doses higher than 0.1 Gy are 
relevant for screening tumors induced by radiation at very low doses. The initial level of stress may 
lead to molecular variations in the cellular response and to the selection of different molecular 
pathways/markers in the tumors. Moreover, radiation-induced tumorigenesis may be modulated by 
specific genetic backgrounds conferring increased radiosensitivity and/or thyroid cancer-prone 
susceptibility as suggested by Detours et al. [29], which could be suspected to have a greater weight at 
low doses. 
8. Conclusions and Perspectives 
Enough data are now available to show that radiation exposure of the thyroid leads to the 
deregulation of molecular markers that can be identified and possibly used for etiology prediction, at Genes 2012, 3                                    
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least for the range of doses for which a significant increase in thyroid tumors can be measured by 
conventional epidemiology (more than 0.1 Gy). However, all the data presented here should be 
considered as preliminary and special caution should be taken to avoid specific pitfalls when analyzing 
molecular specificities of small series of radiation-induced thyroid tumors. All these data should   
be confirmed using larger series of tumors of good quality in terms of RNA Integrity Number (RIN) 
index [58], with the same microarray and hybridization techniques for easier comparisons. For 
example, some studies used tumor-paired normal thyroid tissue for data normalization while others 
used a pool of normal thyroid tissues as an external reference. The methods used to find the signature 
should be adapted to small series of samples. This point is important in fully exploring tumor 
heterogeneity and in limiting the impact of confounding factors. Blind validation of the signatures on 
independent sets of tumors as large as possible is essential to check the pertinence of the signatures. As 
some data suggests that thyroid tumors that develop after external exposure (radiotherapy) or 
131I 
contamination display a common core of molecular markers, co-analysis of post-radiotherapy and 
post-Chernobyl tumors may lead to the identification of a “general” radiation-induced signature   
(for doses higher than 0.1 Gy). This will also help to improve knowledge of radiation-induced 
tumorigenesis by allowing full and rigorous analysis of the specificities and similarities of the 
molecular mechanisms selected as a function of the mode of exposure, the dose and the dose rate. 
Prospective studies will also have to determine what is behind the observed deregulation in radiation-
induced tumors: initial stress effect and/or individual susceptibility to radiation exposure and/or 
thyroid cancer-prone susceptibility. To date, we have no clue to estimate what could be the influence 
of susceptibility compared with the impact of the initial stress in radiation-induced thyroid tumors. 
For the moment the identified signatures cannot be used to screen for tumors induced by very-low-dose 
radiation, for 2 main reasons: (1) the impact of very-low-dose exposure on thyroid tumor risk is still 
unproved, and if it does exist it is extremely small and any biological test should have predictive 
values close to 100% to be used for diagnosis of the few radiation induced thyroid tumors among a 
much larger number of sporadic ones; (2) if the risk exists, we do not know what the signature is and  
if it has something in common with high-dose signatures. Radiation exposure at very low doses in 
animal models that do not develop spontaneous thyroid tumors is needed to estimate the risk. If tumors 
are observed, comparison of molecular signatures of tumors that develop in mice after very low and 
high-dose radiation exposure should be made to define molecular markers and similarities and 
specificities according to doses.  
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